Combining HPV status and intratumour heterogeneity for predicting outcome in head and neck squamous cell carcinoma patients

Evaluation of next-generation sequencing data and associated clinical records of head and neck squamous cell carcinoma patients from several institutions, made available through The Cancer Genome Atlas, showed that combining Mutant-Allele Tumour Heterogeneity as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according to research presented at the 2014 Multidisciplinary Head and Neck Cancer Symposium (20-22 February, 2014, Stottsdale, USA). Read more here.